Description: Sight Sciences, Inc., an ophthalmic medical device company, engages the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology, for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Home Page: seraprognostics.com
SERA Technical Analysis
2749 East Parleys Way
Salt Lake City,
UT
84109
United States
Phone:
801 990 0520
Officers
| Name | Title |
|---|---|
| Dr. Gregory C. Critchfield M.D., M.S. | Exec. Chairman, CEO & Pres |
| Mr. Robert G. Harrison | Chief Information Officer |
| Mr. Benjamin G. Jackson J.D. | Gen. Counsel |
| Dr. Steven W. Graves | Co-Founder and Co-Chairman of The Scientific Advisory Board |
| Dr. M. Sean Esplin M.D. | Co-Founder and Co-Chairman of Scientific Advisory Board |
| Mr. Jay M. Moyes M.B.A., MBA | Chief Financial Officer |
| Dr. John J. Boniface Ph.D. | Chief Scientific Officer |
| Ms. Nadia F. Altomare | Chief Commercial Officer |
| Dr. Paul Kearney Ph.D. | Chief Data Officer |
| Dr. Michael R. Foley M.D. | Chief Medical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.3647 |
| Price-to-Sales TTM: | 166.5979 |
| IPO Date: | 2021-07-15 |
| Fiscal Year End: | December |
| Full Time Employees: | 113 |